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Abstract
Introduction: The aim of the study was to analyse the risk factors of early and
late mortality in patients undergoing the first reoperation for prosthetic valve
dysfunction.
Material and methods: A retrospective observational study was performed in
194 consecutive patients (M = 75, F = 119; mean age 53.2 ±11 years) with
a mechanical prosthetic valve (n = 103 cases; 53%) or bioprosthesis (91; 47%).
Univariate and multivariate Cox statistical analysis was performed to determine
risk factors of early and late mortality.
Results: The overall early mortality was 18.6%: 31.4% in patients with symptoms
of NYHA functional class III-IV and 3.4% in pts in NYHA class I-II. Multivariate
analysis identified symptoms of NYHA class III-IV and endocarditis as
independent predictors of early mortality. The overall late mortality (> 30 days)
was 8.2% (0.62% year/patient). Multivariate analysis identified age at the time
of reoperation as a strong independent predictor of late mortality.
Conclusions: Reoperation in patients with prosthetic valves, performed urgently,
especially in patients with symptoms of NYHA class III-IV or in the case of
endocarditis, bears a high mortality rate. Risk of planned reoperation, mostly in
patients with symptoms of NYHA class I-II, does not differ from the risk of the
first operation.
Key words: prosthetic valve, reoperation, echocardiography.
Introduction
Artificial mechanical valves and bioprostheses which are implanted
nowadays are highly durable and with little thrombogenicity [1-4]. However,
redo surgeries in patients with implanted artificial valves are still a serious
problem; this is so mainly because of the higher early mortality rate. In
studies which have been published so far and which are based on analyses
of a large amount of data [5-9], the authors usually presented the results
of redo surgery performed during a period of about 30 years. A significantly
higher early surgical mortality rate has already been reported before [7,
9, 10]. During the period included in the analysis, trans-oesophageal
echocardiography was the basic method used in recognizing dysfunctions
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of artificial valves and in qualifying for redo surgery
treatments [11, 12].
Therefore the aim of our study was to analyse
the risk factors of early and late mortality in
patients undergoing a redo operation for prosthetic
valve dysfunction.
Material and methods
Patients’ characteristics
The material includes 194 successive patients
with implanted artificial mechanical valves or with
bioprostheses who were qualified to undergo
a reoperation because of a valve prosthesis
dysfunction between 1995 and 2006 in our
department. Intraoperative diagnosis confirming
the recognition was necessary for the patient to be
included in the studied group. According to the
proposition of Clark et al. [13], redo surgery was
understood as reimplantation of a valve prosthesis
which was implanted earlier.
The group of 194 patients contained 75 men 
and 119 women aged between 18 and 74 years (mean
age 53.2 ±11 years). The period between the
implantation of an artificial valve and a redo pro  -
cedure ranged from 6 days to 19 years. A hundred
and twenty patients had an artificial mitral valve
implanted (62 of them had a bioprosthesis) and 
36 patients had an artificial aortic valve implanted 
(13 of them had a bioprosthesis). Thirty-five patients
had both a mitral valve and an aortic valve implanted;
13 of them had two bioprostheses. Three patients had
a biological valve and a mechanical valve implanted. 
Twenty-two patients underwent redo surgery
within 30 days from the implantation of an artificial
valve. Forty-two redo procedures were performed as
urgent indications. A hundred and five patients (54%)
were recognised as NYHA class III/IV. Atrial fibrillation
was diagnosed in 145 patients. Structural dysfunction
was the cause of redo procedure in 6 patients with
a mechanical valve and in 76 patients with
a bioprosthesis. Infectious endocarditis was
recognised in 58 patients. In 30 patients with
a mechanical valve a thrombus was the cause of
blockage of the disc. Seventeen patients had
a paravalvular shunt which was not connected with
the ongoing endocarditis. Seven patients with
mechanical valves underwent redo surgery because
of other reasons (Table I). This time was the shortest
for the infectious endocarditis. Thrombotic
complications which occurred during the period
between the implantation of an artificial valve and
redo surgery were recognised in 17 patients. 
Protocol of the study 
When making a decision concerning redo surgery,
the authors used the protocol adopted for
recognising dysfunctions of artificial valves. If
a dysfunction of an artificial valve was recognised
on the basis of transthoracic examination, the
decision concerning the resignation from
transoesophageal examination was made after
Age [years] Mean (from-to) 53.2 ±11 (18-74)
Sex Men  (%)/Women 75 (39)/119
Time from implantation of PV [months] Mean (from-to) 83.4 ±65.6 (1-230)
Reoperation:    ≤ 30 days n (%) 22 (12.4)
31-180 days  n (%) 38 (19.6)
> 180 days  n (%) 132 (68.0)
Urgent reoperation                                       n (%) 42 (21.7)
Atrial fibrillation                                            n (%) 145 (74.7)
NYHA class III/IV n (%) 105 (54.1)
PV mechanical/bioprosthesis n (%) 103 (53.1)/91
Embolic complications                                                  n (%) 17 (8.7)
The reason for reoperation
Structural dysfunction of mechanical PV            n (%) 6 (3.1)
Structural dysfunction of bioprosthesis        n (%) 76 (39.2)
Infectious endocarditis           n (%) 58 (29.9)
Disc blockage by thrombus    n (%) 30 (15.5)
Paravalvular shunt    n (%) 17 (8.8)
Other*              n (%) 7 (3.6)
*Temporal prosthetic valve dysfunction of unknown aetiology – 3 patients, pannus – 2 patients, “small” prosthetic valve – 2 patients, 
NYHA – New York Heart Association, PV – prosthetic valve 
Table I. Characteristics of the entire study group – 194 patients reoperated on for a prosthetic valve (PV) dysfunctionArch Med Sci 2, April / 2011 273
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consultation with a cardiac surgeon. In order to
achieve the aims of this study, the authors analysed
numerous preoperative clinical and echocardiographic
parameters as well as surgical data.
Cardiac surgical procedures 
In 152 patients the redo procedure involved only
replacement of an artificial valve. In 42 patients
aorto-coronary bridging or tricuspid annuloplasty
was performed. Heart muscle protection was not
significantly different in the patients undergoing
redo surgery at the same time. 
Statistical analysis
Continuous variables were expressed as the
mean value ± SD; Student’s t-test was used to
perform a comparative analysis [14, 15]. Categorical
variables were expressed as percentages and the
χ2 test or Fisher test was used for comparison [14,
15]. Results were recognised as statistically
significant when p < 0.05. A multifactorial analysis,
the Cox proportional hazard models [16], was
performed using the step method, separately for
early mortality rate and late mortality rate. The
Statistica software package was used for statistical
analysis (StatSoft Poland).
Results
Early mortality (≤ 30 days) in the patients who
underwent redo surgery because of the dysfunction
of an artificial valve (Table II) was 18.6%: 31.4% in
patients with symptoms of NYHA functional class
III-IV and 3.4% in pts in NYHA class I-II. It was found
that the following parameters have a significant
influence on the result of a redo procedure: urgent
indications (p < 0.01), NYHA class III/IV (p < 0.001),
infectious endocarditis (IE) (p < 0.001), redo surgery
of an artificial mechanical valve (p < 0.005), kidney
insufficiency (p < 0.05), atrial fibrillation (p < 0.02),
liquid in the pericardium (p < 0.05) and ejection
fraction (EF) < 55% (p < 0.01). The multifactorial
analysis showed that the following were
independent and significant negative prognostic
factors: NYHA III-IV (odds ratio [OR] =3.89, p = 0.01)
and infectious endocarditis (OR = 3.99, p < 0.01). 
The analysis of factors deciding about the results
of redo surgery performed because of infectious
endocarditis revealed the significant influence of
the following parameters on the result of redo
surgery: urgent indications (p < 0.02), NYHA III/IV
(p < 0.001), time from the implantation of an
artificial valve (p < 0.02), kidney insufficiency 
(p < 0.01), liquid in the pericardium (p < 0.05) and
EF < 55% (p < 0.01). The multifactorial analysis
showed that NYHA III-IV (OR = 4.02, p = 0.01) and
ejection fraction below 55% (OR = 3.1, p < 0.01) are
significant independent negative prognostic factors.
In the group of 136 patients who underwent
a redo procedure because of an artificial valve
dysfunction caused by reasons other than infectious
endocarditis (Table III) the following four significant
Death (n = 36) Survival (n = 158) Value of p
Age [years] Mean (from-to) 54.2 ±10.3, 21-71 53.0 ±11.3, 18-74 NS
Sex Men/Women   n 12/24 65/93 NS
Urgent indications n 14 28 < 0.01
NYHA class III-IV n 33 72 < 0.001
Time from PVI [months] mean, med., from-to 45.9 ±63, 8, 1-224 92.1 ±62, 96, 1-230 < 0.001
≤ 30 days, n  11 14
31-180 days, n  20 17
> 180 days, n  5 127
One valve                                              n 30 129 NS
Two valves   n 62 9 N S
PV mechanical/bioprosthesis  n 27/9 76/82 < 0.005
Additional procedures  n 93 3 N S
Infectious endocarditis n 14 44 < 0.001
Arial fibrillation n 33 112 < 0.02
Kidney insufficiency n 3 2 < 0.05
Liquid in the pericardium  n 7 6 < 0.05
Ejection fraction < 55%   n 22 54 < 0.01
med. – median, PVI – prosthetic valve implantation
Table II. Clinical and echocardiographic predictors of death in early postoperative period in 194 patients reoperated
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negative prognostic factors were distinguished:
NYHA III-IV (p < 0.001), time from the implantation
of an artificial valve (p < 0.02), redo surgery of
a mechanical valve (p < 0.02) and atrial fibrillation
(p < 0.01). The multifactorial analysis showed that
NYHA III-IV (OR = 1.58, p  < 0.05) is the only
significant independent negative prognostic factor.
The comparative analysis of the patients who
underwent redo surgery because of infectious
endocarditis and because of other reasons is
presented in Table IV. It revealed that men
significantly outnumbered women in the IE group
(p < 0.01) and that there is no significant difference
between the ages of the patients undergoing redo
surgery. Redo procedures due to reasons other than
IE were performed significantly later (median 
109 months, for IE 15 months, p < 0.001). The
analysis of the direct cause of redo surgery in
patients with an implanted mechanical valve showed
that valvular shunt occurred significantly more often
Death (n = 22) Survival (n = 114) Value of p
Age [years] Mean (from-to) 54.57 ±8.7 (38-69) 53.91 ±10.7 (18-73) NS
Sex Men/Women   n 4/18 40/74 NS
Urgent indications                                  n 52 0 N S
NYHA class III-IV   n 20 48 < 0.001
Time from PVR [months] mean, med., from-to 105.9 ±60, 114, 0-230 < 0.02
≤ 30 days; n  78
31-180 days; n  12 7
> 180 days; n  39 9
One valve  n 20 93 NS
Two valves                                               n 22 1 N S
PV mechanical/bioprosthesis  n 15/7 45/69 < 0.02
Additional procedures                              n 62 3 N S
Prosthetic valve dysfunction* n 15   45   –
Disc blockage n 7   23 NS
Paravalvular leak n 5 12 NS
Structural degeneration n 2 4 NS
Other n 1   6 NS
Atrial fibrillation                          n 21 84 < 0.01
Ejection fraction < 55%                       n 11 40 NS
PVI – prosthetic valve implantation, *refers to patients operated on for mechanical prosthetic valve dysfunction
Table III. Clinical and echocardiographic predictors of perioperative death in patients referred for reoperation due to
causes of prosthetic valve dysfunction other than endocarditis
IE + (n = 58) IE – (n = 136) Value of p
Age [years]                       Mean (from-to) 51.43 ±12.49 (21-74) 54.0 ±10.4 (18-73) NS
Sex                         Men/Women   n 31/27 44/92 < 0.01
Time from PVI [months] mean, med., from-to 49.3 ±56, 15, 1-190 98.9 ±64, 109, 1-230 < 0.001
Bioprostheses n (%) 13 (22.4) 76 (55.9) < 0.001
Direct cause of mechanical PV reoperation 
Disc blockage  n (%) 16 (35.6) 30 (50.0) NS
Paravalvular leak  n (%) 24 (53.3) 17 (28.3) < 0.02
DB + PL n (%) 5 (11.1) – –
Other n (%) – 13  (21.7) –
med. – median, IE – endocarditis, PVI – prosthetic valve implantation
Table IV. Characteristics of patients reoperated on for prosthetic valve (PV) dysfunction due to infective endocarditis
(IE +) and other reasons (IE –)Arch Med Sci 2, April / 2011 275
Redo surgery risk in patients with cardiac prosthetic valve dysfunction
in the patients with IE. Co-occurrence of valvular
shunt and blockage of a heart valve disc was
observed only in patients with IE. The patients with
an implanted bioprosthesis constituted a significantly
smaller subgroup among the patients who
underwent redo surgery because of IE (p < 0.001).
Late results (> 30 days) in the patients who
underwent redo surgery because of the dysfunction
of an artificial valve amounted to 8.2%. The
observation time ranged from 4 to 132 months, 
63 months on average; the total observation time
amounted to 749.5 years. Late mortality rate was
0.62% per patient-year. It was revealed that the
following parameters had a significant influence on
the late result of redo surgery: a patient’s age at
the moment of redo surgery (p < 0.01), male sex 
(p < 0.01), redo procedure of a mechanical valve 
(p < 0.05) and atrial fibrillation (p < 0.05). The
multifactorial analysis showed that the age of
a patient at the moment of redo surgery was an
independent and significant negative prognostic
parameter (OR = 2.29, p < 0.05). Nineteen patients
(12%) underwent another redo procedure, including
5 patients (26.3%) who died during the perisurgical
period.
Discussion
Structural dysfunction of a mechanical valve was
a cause of redo surgery in 3% of the patients.
A similar percentage of structural dysfunctions was
observed by Bortolotti et al. in a group of 
549 patients who underwent a redo procedure
within a period of 26 years [11]. In the present study,
the most frequent cause of a redo procedure 
was structural dysfunction of a bioprosthesis 
(76 patients – 39.2%). Other authors indicate
degeneration of a bioprosthesis as the most
frequent cause of redo surgery as well [7, 17]. Each
patient whose survival time is long enough needs
redo surgery and this is connected with the limited
durability of a bioprosthesis [18]. Taking that into
account, it is proposed that implantation of
bioprostheses be limited to patients over the age of
65. Summing up the results of a 15-year randomized
study which compared bioprostheses and
mechanical valves, Hammermeister et al. [19] stated
that redo procedures occurred significantly more
frequently only in a group of patients below the age
of 65. In the presented material, a direct indication
for redo surgery in a majority of the patients was
valve incompetence (77.6%) and only in 17 cases
was it the stenosis of a bioprosthesis. Only 
5 patients underwent redo surgery urgently; the other
ones underwent a redo procedure according to the
schedule. These patients were re-examined every
3-6 months within the last year before the redo
surgery. The diagnostic procedure which was used
and the percentage of patients who underwent
a redo procedure according to the schedule did not
differ from other authors’ reports [17].
In the present study, the early mortality rate was
18.6%. Other authors reported mortality rates from
6% to 41% [7, 9, 10, 20-22] depending on many
factors connected with the clinical condition of
a patient, advancement of valve pathology and the
surgical procedure used.
This research confirmed the earlier observations
[5, 14, 22, 23] concerning the negative prognostic
influence of NYHA class III-IV and urgent redo
surgery performance on the perisurgical mortality
rate. In the present study, the mortality of patients
who underwent redo surgery in NYHA class III/IV
was 31.4% compared to 3.4% in NYHA class I/II.
Similarly, for redo procedures performed urgently
it was 33% and for scheduled treatments 14.5%.
Urgent recommendations were not a negative
factor in patients undergoing redo procedures
because of valvular dysfunction resulting from
reasons other than infectious endocarditis (Table
III). However, redo surgery cannot be treated as an
independent negative prognostic factor because
a majority of patients treated urgently were in
NYHA class IV. In the group presented by Husebye
et al. [15] only one of 223 patients undergoing
scheduled redo surgery and 64% of patients
undergoing a redo procedure urgently were in NYHA
class IV. These authors assessed the risk of redo
surgery performed according to schedule as 1.3%.
In the present study, 33% of patients undergoing
scheduled redo surgery were in NYHA class III/IV.
These differences might have resulted in a higher
mortality rate in the perisurgical period. Like the
redo procedure, the time which elapsed from the
first surgery is related to the functional condition.
Patients who underwent redo surgery up to 180
days after the implantation of a valve were usually
in NYHA class III/IV and in those cases the results
of redo surgery were worse (Tables II-IV).
Structural dysfunction of a bioprosthesis does
not increase the perisurgical risk if the surgery is
performed according to schedule [24]. In the
present study, the mortality rate was lower by 10%
(71 out of 76 patients underwent scheduled redo
procedures). The opinions of other authors are
similar [7, 25, 26].
Infectious endocarditis usually [27] significantly
increases the risk of perisurgical death (from 24%
to 62.5%). In the present study, the mortality rate
was only 24%, although all patients were in NYHA
class III/IV and 9 out of 14 treated patients
underwent redo surgery urgently. The multifactorial
analysis revealed that infectious endocarditis is an
independent factor which is prognostically negative.
Additional redo procedures are burdened with
an increasing perisurgical mortality rate. The risk
of the second redo surgery is only slightly higher276 Arch Med Sci 2, April / 2011
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[22] but the risk of the third redo surgery and of
subsequent ones is significantly higher at 45% [27].
Similarly, in the present study, the mortality rate
because of further redo surgery was only slightly
higher at 26.3%. 
In the present study, ejection fraction lower than
55% was a negative prognostic factor in perisurgical
mortality only in the group of patients with
infectious endocarditis (Tables II, IV). It seems that
it is mainly connected with quickly increasing
valvular shunt, which haemodynamically cor  -
responds to acute mitral or aortic incompetence.
Turina et al. [28] did not find that a decrease in
ejection fraction < 50% had an influence on
perisurgical mortality in patients with an artificial
valve dysfunction which led to valvular stenosis.
However, they observed a tendency (not statistically
significant) towards worsening of redo surgery
results in patients with a dysfunction which led to
mitral or aortal incompetence. Other analysed
echocardiographic factors were not prognostically
influential or were closely connected with functional
condition (atrial fibrillation, kidney insufficiency or
liquid in the pericardium). 
Late mortality occurred in 0.62% of patients per
year. The only independent factor which was
prognostically negative was the age of the patients
at the moment of redo surgery. Other authors have
pointed to the importance of population factors [21,
27] and the functional condition (NYHA class IV) [7,
8]. In the opinion of Edwards et al. [29], the factors
which negatively influence the late results of redo
procedures performed because of infections of an
artificial valve were the age of the patient and the
replacement of a biological valve with a mechanical
one. 
In conclusion, redo procedures of patients with
implanted artificial valves performed urgently,
particularly in patients in NYHA class III/IV, and
caused by infectious endocarditis, are burdened
with a very high risk. However, the risk of scheduled
redo surgery, particularly in patients in NYHA class
I/II, does not differ from the risk of the first surgery
which is implantation of a valve. Urgent redo
surgery, burdened with a high risk, is necessary only
in patients in NYHA class III/IV with valvular
thrombosis, which results in the blockage of a valve,
and with contraindications to thrombolytic
treatment, as well as in patients with structural
dysfunction of a mechanical valve or infectious
endocarditis. Redo procedures in those patients
should be performed as early as possible in order
to avoid complications, particularly systemic
embolism and cardiogenic shock. Other patients’
condition usually improves after medical treatment
which, most frequently, makes it possible to change
the redo surgery qualification from urgent to
scheduled. It is also important to distinguish
patients with higher risk of redo surgery from
patients with implanted artificial valves. This
concerns particularly bioprostheses and some
mechanical valves as well as patients with
recognised “mild valvular shunt”. 
According to generally accepted standards [15,
30], there are no recommendations for routine
echocardiographic examinations in patients with
implanted artificial mechanical valves. However, it
should be considered to provide patients with
valves of “an old type”, particularly bell and cage
valves and some disc valves [20, 25, 28] as well as
patients with high risk of thrombotic-embolic
complications with such examinations. Patients
with “mild valvular shunt” also need routine
examinations because the degree of their illness
may increase [26]. Unlike cases with mechanical
valves, there is a common consensus of opinion [15,
30] that it is necessary to monitor patients with
implanted bioprostheses using echocardiography,
particularly if the first symptoms of valve
degeneration appear.
The aim of echocardiographic examination in
patients with valvular thrombosis which causes
blockage of the valve is to single out those cases
where the probability of medical treatment
effectiveness is low and which require urgent
reoperation. Echocardiographic examination is of
particular significance in patients with dysfunction
of an artificial valve caused by infectious
endocarditis [31]. 
The present study has some limitations. The
study group contained a small number of patients
with old generation valves in which structural
dysfunctions occurred more frequently. The majority
of valves implanted nowadays are free from this
complication. It is difficult to compare results
presented by various authors because of differences
concerning the analysed periods, material,
methodology and lack of a common definition for
redo procedure which would be accepted by all
authors. 
The research which was carried out and the
analysis of the literature make it possible to propose
an algorithm for treatment in patients qualified for
reoperation because of valve dysfunction based
mainly on echocardiographic assessment. 
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